地舒单抗与唑来膦酸治疗前列腺癌骨转移的临床效果  

Clinical effect of denosumab and zoledronic acid on bone metastasis of prostate cancer

作　　者：何清柳 刘维辉[1] 蔡隆渤 阴煜明 黄庭芳[1] HE Qingliu;LIU Weihui;CAI Longbo;YIN Yuming;HUANG Tingfang(Department of Urology,the Second Affiliated Hospital of Fujian Medical University,Fujian,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属第二医院泌尿外科,福建泉州362000

出　　处：《中国医药科学》2022年第17期169-172,共4页China Medicine And Pharmacy

基　　金：福建省自然科学基金资助项目(2021J01276)。

摘　　要：目的分析地舒单抗与唑来膦酸对前列腺癌骨转移的临床疗效及安全性。方法回顾性分析2020年1月至2022年3月于福建医科大学附属第二医院治疗的前列腺癌骨转移患者18例,按治疗药物分为唑来膦酸组(行唑来膦酸治疗)和地舒单抗组(行地舒单抗治疗),每组各9例。对两组患者治疗前及治疗12周后的骨痛加剧次数、血清碱性磷酸酶(ALP)、不良反应、依从性进行评估分析。结果治疗前与治疗后相比,地舒单抗组相对于唑来膦酸组的骨痛加剧次数显著减少,ALP显著降低,依从性更佳,两组之间比较,差异有统计学意义(P<0.05);两组之间不良反应总发生率比较,差异无统计学意义(P>0.05)。结论较唑来膦酸相比,地舒单抗治疗前列腺癌骨转移临床疗效显著,能减少骨痛加剧次数,显著降低ALP,依从性更佳。Objective To analyze the clinical effectiveness and safety of denosumab and zoledronic acid in the treatment of bone metastasis of prostate cancer.Methods Eighteen cases with bone metastates of prostate cancer,from January 2020 to March 2022 in the Second Affiliated Hospital of Fujian Medical University,were analyzed retrospectively and divided into the zoledronic acid group(treated with zoledronic acid)and the denosumab group(treated with denosumab)according to the treatment drugs,with 9 case in each group.The evaluation of the number of ostalgia intensify,alkaline phosphatase(ALP),adverse reactions and compliance of the two groups were analyzed before and after twelve weeks of treatment.Results Comparing the pre-treatment and post-treatment,the number of ostalgia intensify and ALP of denosumab group was significantly decreased relative to the zoledronic acid group and the compliance of it was better,which made the difference between two groups statistically significant(P<0.05).There was no statistically difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Comparing to the zoledronic acid,the denosumab reveal a significant clinical efficacy in the treatment of bone metastasis of prostate cancer with decreasing the number of ostalgia intensify,reducing the ALP significantly,and leading to better compliance.

关 键 词：地舒单抗 唑来膦酸 前列腺癌 骨转移 骨痛 

分 类 号：R737.25[医药卫生—肿瘤]